EPS for NovoCure Limited (NVCR) Expected At $-0.14

February 13, 2018 - By Clifton Ray

 EPS for NovoCure Limited (NVCR) Expected At $ 0.14

Analysts expect NovoCure Limited (NASDAQ:NVCR) to report $-0.14 EPS on February, 22.They anticipate $0.12 EPS change or 46.15 % from last quarter’s $-0.26 EPS. After having $-0.13 EPS previously, NovoCure Limited’s analysts see 7.69 % EPS growth. The stock increased 0.24% or $0.05 during the last trading session, reaching $20.55. About 360,372 shares traded. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since February 14, 2017 and is downtrending. It has underperformed by 17.13% the S&P500.

NovoCure Limited (NASDAQ:NVCR) Ratings Coverage

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. Deutsche Bank initiated the stock with “Hold” rating in Wednesday, December 2 report. The stock of NovoCure Limited (NASDAQ:NVCR) has “Underweight” rating given on Tuesday, January 19 by Barclays Capital. The rating was initiated by Wedbush on Tuesday, October 27 with “Outperform”. On Tuesday, October 27 the stock rating was initiated by JP Morgan with “Overweight”. JMP Securities initiated NovoCure Limited (NASDAQ:NVCR) rating on Tuesday, October 27. JMP Securities has “Market Outperform” rating and $43 target. Wedbush maintained the stock with “Outperform” rating in Friday, July 29 report.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $1.84 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

More notable recent NovoCure Limited (NASDAQ:NVCR) news were published by: Fool.com which released: “Here’s Why NovoCure Ltd. Is Skyrocketing Today” on April 03, 2017, also Nasdaq.com with their article: “Commit To Buy NovoCure At $15, Earn 14.8% Annualized Using Options” published on July 26, 2017, Nasdaq.com published: “NovoCure Ltd is Now Oversold” on October 13, 2017. More interesting news about NovoCure Limited (NASDAQ:NVCR) were released by: Gurufocus.com and their article: “Novocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of Shares” published on January 16, 2018 as well as Nasdaq.com‘s news article titled: “NovoCure Reaches Analyst Target Price” with publication date: September 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: